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trial of early sedation management using
Responsiveness Index monitoring in
mechanically ventilated critically ill patients
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and Timothy S. Walsh1*Abstract
Introduction: Deep sedation is associated with adverse patient outcomes. We recently described a novel
sedation-monitoring technology, the Responsiveness Index (RI), which quantifies patient arousal using processed
frontal facial EMG data. We explored the potential effectiveness and safety of continuous RI monitoring during early
intensive care unit (ICU) care as a nurse decision-support tool.
Methods: In a parallel-group controlled single centre proof of concept trial, patients requiring mechanical
ventilation and sedation were randomized via sequential sealed envelopes following ICU admission. Control group
patients received hourly clinical sedation assessment and daily sedation holds; the RI monitor was connected but
data were concealed from clinical staff. The intervention group received control group care, but RI monitoring was
visible and nurses were asked to adjust sedation to maintain patients with an RI>20 whenever possible. Traffic-light
colour coding (RI<20, Red; 20–40, Amber; >40, Green) simplified decision-making. The intervention lasted up to
48 hours. Sixteen nurses were interviewed to explore their views of the novel technology.
Results: We analysed 74 patients treated per protocol (36 intervention; 38 control). The proportion of patients with
RI<20 was identical at the start of monitoring (54 % both groups). Overall, the proportion of time with RI<20
trended to lower values for the intervention group (median 16 % (1–3rd quartile 8–30 %) versus 33 % (10–54 %);
P = 0.08); sedation and analgesic use was similar. A post hoc analysis restricted to patients with RI<20 when
monitoring started, found intervention patients spent less time with low RI value (16 % (11–45 %) versus 51 %
(33–72 %); P = 0.02), cumulative propofol use trended to lower values (median 1090 mg versus 2390 mg; P = 0.14),
and cumulative alfentanil use was lower (21.2 mg versus 32.3 mg; P = 0.01). RASS scores were similar for both
groups. Sedation related adverse event rates were similar (7/36 versus 5/38). Similar proportions of patients had
sedation holds (83 % versus 87 %) and were extubated (47 % versus 44 %) during the intervention period. Nurses
valued the objective visible data trends and simple colour prompts, and found RI monitoring a useful adjunct to
existing practice.
Conclusions: RI monitoring was safe and acceptable. Data suggested potential to modify sedation
decision-making. Larger trials are justified to explore effects on patient-centred outcomes.
Trial registration: NCT01361230 (registered April 19, 2010)* Correspondence: twalsh@staffmail.ed.ac.uk
1Anaesthetics, Critical Care and Pain Medicine, Centre for Inflammation
Research and School of Clinical Sciences, Edinburgh University, 51 Little
France Crescent, Edinburgh, Scotland EH16 4SA, UK
Full list of author information is available at the end of the article
© 2015 Kaila et al. Open Access This article is
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zedistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Kaila et al. Critical Care  (2015) 19:333 Page 2 of 10Introduction
Most mechanically ventilated critically ill patients re-
quire sedation and analgesia. Deep sedation is associated
with adverse outcomes including higher mortality [1, 2],
and strategies that systematically avoid over-sedation im-
prove patient outcomes in both randomised trials [3–6]
and quality improvement studies [7–9]. Conversely, light
sedation and agitation can compromise patient safety
and increase staff workload and stress [10–12].
Recent guidelines recommend the systematic evalu-
ation of pain, agitation, and delirium in intensive care
units (ICUs) and implementation of evidence-based
strategies to improve patient experience and outcomes
[13, 14]. Although there are valid and reliable clinical
tools for diagnosing and rating pain, sedation and delir-
ium [15], the implementation of practices that identify
and systematically avoid unnecessary deep sedation is
challenging. There are several technologies for monitoring
sedation status based on electroencephalogram (EEG)
analysis, but these were developed primarily for monitor-
ing the depth of anaesthesia and their validity for use in
ICU patients is uncertain [16]. Although these algorithms
correlate with clinical sedation scores, their discriminant
ability is limited, in part because of interference from
facial frontal electromyelogram (fEMG) signals during
arousals and in lighter sedation states [17, 18]. There
have been few randomised trials of these technologies,
and the available data do not support clinical effect-
iveness [13, 19].
We recently described a novel technology for conti-
nuous monitoring of patient status in ICU patients,
the Responsiveness Index (RI), based on fEMG activity
[20–22]. The algorithm uses fEMG data acquired via
adhesive surface forehead electrodes, and utilises the pre-
vious 60 minutes of fEMG activity to assess the frequency
and intensity of arousals during ongoing treatments. RI
has been shown to perform better than an EEG-based
algorithm [21], and to have face and criterion validity
compared with clinical sedation states [20].
Our aim in this proof-of-concept trial was to assess
the effectiveness, safety, and acceptability of continuous
RI monitoring during early ICU care as a nurse
decision-support tool. We hypothesised that continuous
RI monitoring as an adjunct to clinical sedation scoring
would decrease the period of low patient responsive-
ness without excess adverse events, compared to a
control group treated according to current best prac-
tice. We aimed to use both quantitative and qualitative
approaches to provide early effectiveness, safety and ac-
ceptability data.
Methods
We undertook a prospective single-centre randomised
parallel-group controlled proof-of-concept trial, includingqualitative analysis of interviews with nursing staff utilis-
ing the RI monitor.Patients and setting
The study took place in an 18-bed Scottish general adult
ICU admitting approximately 650 ventilated medical,
surgical, and trauma patients annually (excluding routine
cardiac surgery and neuro-intensive care). Patients were
screened by clinical nursing staff at the time of ICU
admission. Inclusion criteria were that patients were
mechanically ventilated via an endotracheal tube, and
receiving intravenous sedation with a hypnotic agent by
continuous infusion. Exclusion criteria were patients
who had a primary intracerebral disorder (including
post-cardiac arrest, intracranial haemorrhage, or head
injury causing a reduced level of consciousness prior to
intubation); were already conscious at the time of enrol-
ment defined as Richmond agitation-sedation scale
(RASS) score [23] ≥ −1; were aged <16 years; were not
expected to survive the next 24 hours; were receiving
long-term ventilation prior to ICU admission; had a
long-term tracheostomy prior to ICU admission; had
been transferred sedated and mechanically ventilated
from another ICU (unless recruitment was possible
within 24 hours of the first ICU admission); were receiv-
ing continuous neuromuscular blocking agent (NMBA)
at the time of screening; had previously been enroled in
the trial; had status epilepticus; had confirmed meningi-
tis or encephalitis, or had a known chronic neurological
disease interfering with normal neuromuscular function,
e.g., motor neurone disease, Guillain-Barre syndrome or
inherited neuromyopathy.Consent and randomization
Consent was deferred to enable the establishment of re-
sponsiveness monitoring close to the time of ICU admis-
sion. Relatives or next of kin were approached at the
earliest opportunity following admission for consent
to remain in the study; patients were approached
when they had capacity. Patients in whom consent
was not subsequently obtained from a relative, or pa-
tients who were withdrawn from the trial were ex-
cluded from the analysis (according to Scottish legal
requirements). Patients were randomised by nursing
staff to one of the two groups by opening sequentially
numbered opaque sealed envelopes. The randomisation
order was generated using a computer randomisation se-
quence. No stratification or minimisation was used. The
allocation within each envelope directed the clinical
nurse to select an RI monitor pre-specified to the
control or intervention group (see below). The study was
approved by the Scottish A Research Ethics committee
(09/MRE00/17).
Fig. 1 Responsiveness Index (RI) sedation monitor used in the trial.
For intervention patients, the screen presented a running trend over
several hours, with the most recent value presented on an arbitrary
scale of 0–100, with a colour code of RED (<20), AMBER (20 to 40);
and GREEN (>40). In addition to the colour trend, the following prompts
were automatically presented according to RI value: RED high risk of
over-sedation. Ensure adequate analgesia if responsive to stimuli, e.g.,
suctioning/physiotherapy. Reduce sedation dose if no eye-opening to
physical stimuli. AMBER: moderate risk of over-sedation. Ensure adequate
analgesia. Reduce sedation if no eye-opening to physical stimuli. GREEN:
low risk of over-sedation. Ensure adequate analgesia. Continue
current sedation unless patient agitated
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All participating nursing staff received pre-trial training
in the use of the Responsiveness monitor, and the con-
cept that low RI values are expected for deeply sedated
patients, for some patients in a coma unrelated to sed-
ation, and during natural sleep [20]. Nurses were also
instructed not to use monitor data when patients re-
ceived NMBAs.
Control group (group 1)
All patients were attached to the Responsiveness moni-
tor, and data were acquired using a laptop computer.
For these patients a monitoring device was used, which
did not display any RI data throughout the study. RI data
could only be accessed by code by the research team (to
check quality etc.), which was not available to clinical
staff. The monitor presented an automated prompt every
hour during the study to assess the RASS score and
enter it into the study case record form (CRF). The
prompt flashed on the monitor until a score was en-
tered, and the exact time of entry logged. The local sed-
ation protocol encouraged staff to target a RASS score
of >−3 and to undertake a sedation hold on a daily basis
unless clinically contraindicated.
Intervention group (group 2)
As for group 1, all patients in the intervention group
were attached to the Responsiveness monitor, and data
collected using a laptop computer. For these patients RI
data were presented as a continuous trend, with a numeric
value (0–100), and a colour code (red, amber, green) ac-
cording to our previous published work, which suggested
a value with a red colour had sensitivity to detect patients
who may be excessively sedated [20]. An example of a
monitor during use is shown in Fig. 1. Prompts accom-
panied the colour of RI presented on the screen, to en-
courage sedation reduction for patients with a red or
amber RI value (RI <40). Nurses were asked to alter sed-
ation using clinical judgement to transition patients out of
the red RI range and adjust sedation to achieve values in
the amber/green range. In addition, automated prompts
occurred every hour for RASS scores as for group 1.
Management during intervention period
The choice of sedative and analgesic drugs, and the ini-
tial dosage, was at the discretion of the clinical team.
The standard sedative drug was propofol, and the opiate
alfentanil at the time of the study. Clinicians could use
alternative agents, principally midazolam and morphine,
according to clinical discretion. All decisions about other
aspects of usual care were made by the clinical team, in-
cluding the timing of extubation. The only trial-specific
interventions were related to changes in the dose of sed-
atives made by bedside nursing staff in the two studygroups. The research team, who were the only individuals
with access to the RI data for the control group, was not
involved in clinical management.
Study endpoints
Responsiveness monitoring was continued until one of
the following endpoints occurred:
1. 48 hours had elapsed from ICU admission
2. The patient was extubated
3. The patient died or a decision was made to
withdraw treatment
The maximum duration of RI monitoring was 48 hours.
This duration was chosen pragmatically for the proof-of-
concept study, and to enable comparison for a fixed
period of care during which excessive sedation is known
to be associated with adverse outcomes [1].
Discontinuing RI monitoring
RI monitoring could be discontinued for procedures or
other reasons according to clinical judgement. In these
cases, monitoring was reattached as soon as feasible if
within the 48 hour intervention period.
Data collection
Baseline data were age, gender, admission diagnosis, time
from hospital to ICU admission, acute physiology and
chronic health evaluation (APACHE) II score, Charlson
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(SOFA) score (excluding neurological score) for the first
24 hours (range 0–20), RASS score at the start of moni-
toring, and intravenous sedation and analgesic drug use in
ICU prior to RI monitoring. Hourly data collection during
the intervention period was RASS score, and intravenous
sedative and analgesic dose. The use of formal sedation
holds was recorded on a daily basis. The following pre-
defined sedation-related adverse events were recorded:
unplanned extubation, unplanned removal of vascular
catheter, unplanned removal of nasogastric/enteral tube,
episode of myocardial ischaemia, myocardial infarction
and agitation requiring pharmacologic treatment.
Outcomes
Our feasibility outcomes were to test the protocol and
determine likely recruitment rates for a large trial. To
explore potential clinical effectiveness, acceptability, and
safety we measured the following additional outcomes:
1. Proportion of time spent with low responsiveness
(red colour code; RI <20) during the first 48 hours
in ICU (or from when first sedated and ventilated)
2. Proportion of time spent with RASS score −4/−5
during first 48 hours (or from when first sedated
and ventilated)
3. Sedation-related adverse event rates (comparison of
control and intervention groups during intervention
period)
4. Duration of mechanical ventilation
5. ICU, hospital mortality
6. Total sedative drug dose during first 48 hours in the
ICU (or from when first sedated and ventilated)
7. Total opioid drug dose during first 48 hours in the
ICU (or from when first sedated and ventilated)
We described patient status at 48 hours and 7 days
post-randomisation. The full trial protocol is available in
the additional material (see Additional file 1), and is
registered at ClinicalTrials.gov: NCT01361230.
Sample size
This was a proof-of-concept study so no formal sample
size estimation was undertaken. We aimed to randomise
60–70 patients to assess feasibility and provide prelimin-
ary efficacy and safety data. Based on ICU admission
rates (650 mechanically ventilated cases per year), and
an estimated 20–30 % enrolment rate for eligible patients,
we planned to recruit for a fixed period of 8 months.
Analysis
The intervention period was defined as the start of
monitoring to 48 hours post ICU admission. Baseline RI
was defined as the first valid RI value recorded. For RIanalyses patients in whom monitoring was removed be-
cause the patient was extubated were assumed to have
an RI value >20 during the post-extubation period.
Periods during which NMBAs were used, plus the 30
minutes after discontinuation, were censored from the
analysis period. No deaths occurred during the 48-hour
intervention period, so competing risk of death was not
relevant.
RASS data were pre-processed to impute missing data
using several rules: first, if RASS scoring was not performed
during a particular hour, the subsequent hourly RASS value
was utilized in the analysis; if the subsequent hour had no
RASS value, the previous hourly value was used; if neither
value was available then that hour was considered to have
no RASS data point. For comparisons of total intravenous
sedative and analgesic dose during the intervention periods
propofol and alfentanil equivalents were calculated for
patients who received midazolam and/or morphine as
an alternative or addition to propofol/alfentanil. We
used a conversion factor of 1 mg midazolam = 10 mg
propofol, and 1 mg morphine = 100 μg alfentanil.
Prior to the trial we had no data to inform the distri-
bution of RI values at enrolment. As the intervention
aimed to promote transition from an RI value of <20
(red colour code) to higher RI values (amber/green colour
code) we undertook a post hoc subgroup analysis for
patients with baseline RI <20. We justified this analysis
because for this group the protocol directed nursing staff
to decrease sedation at enrolment, whereas for patients
with RI values >20 the protocol did not direct nurses to
alter sedation based on the intervention.
As this was a proof-of-concept study, we restricted ana-
lysis to patients treated per protocol with the monitor. We
used the Wilcoxon rank-sum test to compare continuous
non-parametric data, and Fisher’s exact test for categorical
data. The log-rank test was used to compare time to first
RI value >20, first RASS score >−4, and time to extubation.
A P value <0.05 was considered statistically significant, but
given the exploratory nature of the study we examined
trends in addition to statistically significant differences.
Qualitative study
Sixteen nurses with at least 12 hours experience using
the monitor in the intervention arm were interviewed to
explore their views of sedation management and the po-
tential value of the RI technology. A phenomenological
theoretical perspective was taken during analysis. The
design of the qualitative study, underpinning theoretical
perspective, and qualitative methods used are described
in full in the additional material (see Additional file 2).
Results
Ninety patients were randomised. No consent was ob-
tained post-randomisation in 12 patients (data could not
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intervention group and 8 in the control group), a proto-
col deviation occurred in 4 patients (the randomisation
procedure was incorrectly followed by clinical nursing
staff in 2 patients, and monitoring was not started by
clinical staff during sedation in 2 patients despite ran-
domisation to the intervention group). We included 74
patients in the analysis (36 in the intervention group and
38 in the control group). Patient characteristics and
baseline data are shown in Table 1. The patient groups
were similar at baseline with respect to all measured var-
iables. Monitoring was started within 8 hours of intub-
ation for >75 % of participants.
During the RI monitoring period, NMBAs were ad-
ministered to 10 patients (6 in the intervention group
and 4 in the control group). These were mostly singleTable 1 Baseline characteristics and patient status at randomisation
Baseline variables
Age, years, median
(1st, 3rd quartile; min–max)
Sex, male/female
Primary diagnosis, number of patients
Cardiovascular
Respiratory
Gastrointestinal
Renal
Trauma
Other
APACHE II score, median
(1st, 3rd quartile; min–max)
Charlson comorbidity index, median
(1st, 3rd quartile; min–max)
SOFA score for first 24 hours, median
(1st, 3rd quartile; min–max)
Time, hours from intubation to start of monitoring, median
(1st, 3rd quartile; min–max)
RI at start of intervention period, median
(1st, 3rd quartile; min–max)
Red, n (%)
Amber, n (%)
Green, n (%)
No value, n (%)a
RASS score at start of intervention period, median
(1st, 3rd quartile; min to max)
Total alfentanil dose, mg, prior to monitoring, median
(1st, 3rd quartile; min–max)
aOne patient in each group had a long delay in commencing Responsiveness Index
not given a baseline RI value, and were excluded from the subgroup analysis of pat
study. APACHE acute physiology and chronic health evaluation, SOFA sequential orgbolus doses (n = 7); other durations were 30 minutes
(n = 2) and 150 minutes (n = 1). The median per-
centage of time without monitoring was 2 % (1st, 3rd
quartile: 0, 7 %) for the intervention and 3 % (0, 8 %)
for the control group.
All intervention group patients and 36/38 control pa-
tients received propofol during the intervention period;
33/36 intervention group patients and 37/38 control pa-
tients received alfentanil. In the intervention group, 4/36
patients received midazolam as did 4/38 control group
patients, and 8/36 patients in the intervention group and
7/38 control group patients received morphine during
the intervention period. These were converted to propo-
fol and alfentanil equivalents as described above.
A comparison of outcomes between the groups is
shown in Table 2. A high perentage of patients (>80 %)Intervention (n = 36) Control (n = 38)
60 59
(44, 69; 25–85) (43, 72; 27–80)
21/15 26/12
8 5
3 9
14 15
0 1
3 1
8 7
20 23
(11, 24; 0–31) (17, 26; 0–38)
1 1
(0, 2; 0–5) (0, 2; 0–7)
7 8
(5, 11; 2–16) (5, 9; 1–16)
4.0 4.9
(2.1, 6.2; 1.0–12.0) (3.5, 7.7; 0.7– 1.8)
16 18
(0, 55; 0–100) (0, 42; 0–100)
19 (54.3 %) 20 (54.1 %)
5 (14.3 %) 8 (21.6 %)
11 (31.4 %) 9 (24.3 %)
1 (2.8 %) 1 (2.6 %)
−3 −4
(−4, −2; −5 to +0) (−4, −3; −5 to +2)
1.75 3.00
(0.75, 5.25; 0.00–14.00) (1.00, 7.50; 0.00–17.50)
(RI) monitoring by clinical staff after randomisation. These two patients were
ients with RI <20 at baseline, as the value was uncertain at the start of the
an failure assessment, RASS Richmond agitation-sedation scale
Table 2 Comparison outcomes during the intervention period and at 7 days post-randomisation for the entire study cohort
Outcome Intervention (n = 36) Control (n = 38) P value
Outcomes during 48-hour intervention period
Proportion of hours during the intervention period with RI value <20, median 16 33 0.08
(1st, 3rd quartile; min– max) (8, 30; 1–87) (10, 54; 0–86)
Time, hours from start of monitoring to first RI value >20, median 0.1 0.3 0.43
(1st, 3rd quartile; min– max) (0.0, 2.2, 0.0–7.8) (0.0, 3.1, 0.0–48)
Proportion of RASS scores of −4 or −5 during the intervention period, median 12 17 0.70
(1st, 3rd quartile; min– max) (0, 35; 0–94) (3, 36; 0–100)
Time, hours from start of monitoring to first RASS score >−4, median 2 3 0.68
(1st, 3rd quartile; min– max) (0, 8, 0–43) (0, 8, 0–48)
Total propofol dose, mg, during the intervention period, median 1,365 1,730 0.64
(1st, 3rd quartile; min– max) (380, 2,790; 50–8,710) 1730 (620, 3,260; 0–8,630)
Total alfentanil dose, mg, during the intervention period, median 23.4 25.2 0.68
(1st, 3rd quartile; min– max) (9.0, 36.4; 0.0–51.5) (8.6, 36.0; 0.3–87.0)
Number (%) of patients undergoing sedation hold during the intervention period 30/36 (83) 33/38 (87) 0.751
Number (%) of patients extubated during the intervention period 17/36 (47.2 %) 17/38 (44.7 %) 1.00
Proportion of hours in intervention period during which patient extubated, median 4 0 0.49
(1st, 3rd quartile; min– max) (0–62; 0–92) (0, 44; 0–97)
Number (%) of patients with any predefined adverse events during intervention period 7/36 (19.4 %) 5/38 (13.1 %) 0.54
Unplanned extubation, number 0 1
Unplanned removal of vascular catheter, number 0 0
Unplanned removal of nasogastric or other enteral tube, number 1 0
Unplanned removal of other drain or device, number
Episode of myocardial ischaemia, number 0 0
Myocardial infarction, number 0 0
Episode of agitation requiring bolus treatment with haloperidol or sedative drug
(rescue medication), number
0 0
6 4
Outcomes at 7 days post-randomisation
Time from start of monitoring to first extubation, hours, median 42.4 54.8 0.52
(1st, 3rd quartile; min– max) (14.7, 168.0; 2.0–168.0) (22.8, 168.0; 1.78–168.0)
Deaths, number (%) 1/36 (2.8 %) 3/38 (7.9 %) 0.62
Discharged from ICU, number (%) 20/36 (55.6 %) 18/38 (47.4 %) 0.50
Still in ICU, number (%) 15/36 (41.7 %) 15/38 (41.7) 1.00
Transferred to another ICU, number (%) 0/36 (0 %) 2/38 (2 %) 0.49
The intervention period was defined as being from the start of monitoring to 48 hours post ICU admission. RI Responsiveness Index, RASS Richmond
agitation-sedation scale
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intervention period, and 34/74 patients (46 %) were
extubated. Among the entire cohort the intervention
group patients tended to have fewer hours with RI <20,
but this was not statistically significant (median 16 %
(quartile 1–3, 8–30 %) versus 33 % (10–54 %); P = 0.08).
Mechanical ventilation status over the 48-hour interven-
tion period is shown in Fig. 2. There were no statistically
significant differences between the groups overall, and
no difference in sedation-related adverse events. In the
post hoc analysis, 53 % of patients had a baseline RIof <20 (19 in the intervention group and 20 in the
control group). Among these patients those in the
intervention group spent less time with RI <20 (16 %
(11–45) in the intervention versus 51 % (33–72) in the
control group; P = 0.02), and also tended to receive
lower cumulative doses of propofol (P = 0.14) and
alfentanil (P = 0.01) (Table 3). Changes in ventilation
and RI status for all patients over the 48 hour-
intervention period are illustrated in Fig. 3a, and for
the sub-group with RI <20 at baseline in Fig. 3b.
These indicated a pattern of quicker extubation and
Fig. 2 Kaplan-Meier curve illustrating the numbers of patients in each trial group (36 in the intervention and 38 in the control group) requiring
mechanical ventilation over the 48-hour intervention period. Log-rank test: P = 0.33
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especially when the baseline RI was <20.Qualitative study
Nursing staff valued the objective visible representa-
tion of sedation state, the simple colour representa-
tion of trends, and the continuous prompt to manage
sedation in contrast to existing intermittent assess-
ments or interventions. The trending was seen as a
useful alert and warning, for example, during sedation
reduction/interruption. The objective data were also
valued in justifying decision-making with medical staff,
especially in relation to wakeful or agitated patients.
Nurses valued the use of the monitor as an adjunct to
decision-making rather being asked to target specific RI
values. A full description of the qualitative data analysisTable 3 Comparison of outcomes for patients analysed in the post ho
Outcome
Proportion of hours during the intervention period with RI value <20, media
(1st, 3rd quartile; min–max)
RASS score at baseline, median
(1st, 3rd quartile; min-max)
Proportion of hours with RASS score −4 or −5 during intervention period, m
(1st, 3rd quartile; min-max)
Total propofol dose (mg) during intervention period, median
(1st, 3rd quartile; min-max)
Total alfentanil dose (mg) during intervention period, median
(1st, 3rd quartile; min-max)
RASS Richmond agitation-sedation scaleand conclusions is provided in the additional material (see
Additional file 2).Discussion
We report the first use of RI monitoring to support
nurse decision-making in relation to early ICU sedation.
Our data suggest that low RI values can safely be used
as a prompt to decrease sedative drug use without
increasing adverse events. The trend towards lower RI
values during the intervention period with RI monitor-
ing, which was statistically significant for the post hoc
subgroup analysis of patients with baseline RI <20, sug-
gest RI monitoring has potential utility for minimising
unnecessary early deep sedation.
The RI index utilises fEMG data from the preceding
60 minutes to provide an overall measure of individualc exploratory analysis with baseline Responsiveness Index (RI) <20
Intervention (n = 19) Control (n = 20) P value
n 16 51 0.02
(11, 45; 2–87) (33, 72; 5–86)
−4 −4 0.76
(−4, −3; −5 to −2) (−4, −3; −5 to 0)
edian 47 35 0.63
(15, 65; 0–94) (10, 72; 0–100)
1,090 2,380 0.14
(375, 2,965; 100–7,290) (1,510, 3,730; 60–8,630)
21.2 32.3 0.01
(8.5, 27.9; 0.0–49.0) (23.3, 49.8; 1.0–87.0)
Fig. 3 Description of the numbers of patients remaining intubated over the 48-hour intervention period, together with the numbers of patients
with Responsiveness Index (RI) values in the Red, Amber, and Green categories at each time point. a Summary of data for for all patients in each
group. b Data restricted to patients in whom the baseline RI value was <20
Kaila et al. Critical Care  (2015) 19:333 Page 8 of 10responsiveness [22]. Our validation studies found that
this was less subject to the “on-off” fEMG artifacts that
can confound the bispectral index and entropy, which
are primarily based on EEG data [17, 21]. RI is intended
to provide an objective integrated measure of patient
arousal in relation to underlying neurological status, ex-
ternal stimulation, and administered sedation and anal-
gesia over the preceding 60 minutes. RI values are low
during deep sedation, but can also be low in other forms
of coma and natural sleep, and during periods of min-
imal external stimulation [20]. These non-linear relation-
ships with sedation and neurological status were the
rationale for using low RI values as a prompt or alert,
rather than using specific values as a sedation target.Despite the need to explore the potential reasons for a
low RI value during decision-making, the interviewed
nurses valued the information. The continuous objective
simple presentation using colour in addition to numeric
data was considered useful, and data were felt to support
decision-making in relation to sedation reduction, but
also to justify maintenance of the current sedation state.
These qualitative findings further supported the RI
concept, especially as many nurses had relatively limited
experience using the technology when interviewed.
This was a proof-of-concept study, and a conveni-
ence sample size was used rather than a calculated
sample size to demonstrate clinically important differ-
ences in patient outcomes. Non-significant trends
Kaila et al. Critical Care  (2015) 19:333 Page 9 of 10towards quicker extubation, higher RI values and lower
sedative drug use were observed in the intervention group,
which mainly occurred in the subgroup in whom RI values
were <20 at baseline, in whom there was greatest plausi-
bility for an effect on clinical management. The frequent
use (>80 %) of sedation holds and a protocol that included
prompted hourly sedation assessment using the RASS
score make it possible that the best practice provided in
both groups decreased the effect size attributable to RI
monitoring. However, our aim in this proof-of-concept
study was to explore the safety and potential effect-
iveness of RI monitoring as an incremental interven-
tion. These preliminary data are consistent with a
potential utility for RI monitoring as an adjunct to
regular clinical assessments, even when these are used
frequently, but further studies are needed to evaluate
the effectiveness of RI monitoring in larger and more
varied ICU settings.
We did not observe significant differences in the RASS
scores either for the overall cohort, or for the analysis
restricted to patients with RI <20 at the start of monitor-
ing. The relatively small patient numbers, wide variation
in RASS scores, categoric nature of RASS data, and low
overall proportion of time with RASS < −4 during the
48-hour intervention period may explain this finding.
Our previous validation studies clearly indicate that clin-
ical sedation scales, which score responses to specific
stimuli at defined time points, are not directly compar-
able to the RI, which is a measure of overall arousal dur-
ing clinical management over the previous 60 minutes of
care [20, 21]. Although the RASS score has good dis-
criminant ability and reliability in published studies [23],
it is potentially subject to recording bias by clinical staff
and is semi-subjective. Our proof-of-concept study pro-
vides quantitative and qualitative data suggesting that
the objective RI data could influence nursing staff des-
pite the frequent (hourly) recording of RASS score.
However, further larger studies are needed to determine
whether RI monitoring can increase overall RASS scores,
and whether this translates into improved sedation qual-
ity and clinical outcomes.
Current evidence-based guidelines do not recommend
the routine use of technologies to guide sedation man-
agement [13]. Published studies with existing technolo-
gies suggest variable discriminant validity, and problems
with artefact suppression and confounding of algorithms
by fEMG frequencies [16, 24, 25]. There are few pub-
lished trials of technology-guided sedation and those
published do not demonstrate benefit [19]. The RI was it-
eratively developed to address the problems encountered
with other technologies, but further trials with power to
detect differences in clinically important outcomes are
needed to further evaluate its clinical effectiveness and
cost-effectiveness.Strengths of our trial include the prospective measure-
ment of multiple proof-of-concept and safety outcomes,
and the inclusion of a nested qualitative study with clin-
ical users. The direct comparison of RI data between the
groups with blinding of RI data from clinical staff in the
control group reduced the chance of bias for this out-
come. Weaknesses include the limited sample size, and
the exclusion from analysis of randomised patients in
whom subsequent consent could not be obtained. How-
ever, for a proof-of-concept trial in which comparisons
of patients treated as per protocol was of the greatest
interest, we think it unlikely that this was an important
source of bias.Conclusions
In conclusion, we have shown that the use of RI monitor-
ing as an adjunct to decision-making by bedside nurses
has potential utility for improving sedation-management
without increasing sedation-related adverse effects. The
technology was acceptable and considered potentially use-
ful by ICU nurses.Key messages
 The Responsiveness Index is a novel
sedation-monitoring technology that may have
clinical utility for modifying nurse decision-making
in mechanically ventilated sedated critically ill
patients
 Altering sedation using Responsiveness-Index-guided
decision support did not increase sedation-related
adverse events
 Nursing staff found Responsiveness Index
monitoring a useful adjunct to decision-making,
particularly the objective continuous data and
simple colour-coded data presentation
 Larger trials of sedation management using
Responsiveness Index monitoring are justifiedAdditional files
Additional file 1: Pilot trial protocol for a randomised controlled
trial of intensive care management of sedation using patient
responsiveness in critical care (IMPROVE). (PDF 399 kb)
Additional file 2: Summary of qualitative analysis of interviews with
ICU nurses regarding their views and opinions of responsiveness
index monitoring in the IMPROVE pilot trial. (PDF 288 kb)Abbreviations
APACHE: acute physiology and chronic health evaluation; CRF: case record
file; EEG: electroencephalogram; fEMG: facial electromyelogram; ICU: Intensive
Care Unit; NMBA: neuromuscular blocking agents; RASS: Richmond
agitation-sedation scale; RI: Responsiveness Index; SOFA: sequential organ
failure assessment.
Kaila et al. Critical Care  (2015) 19:333 Page 10 of 10Competing interests
Financial: this study was funded by a grant from GE Healthcare to Edinburgh
University. GE Healthcare developed the Responsiveness Index technology in
collaboration with TSW and Edinburgh University; GE Healthcare holds
patents for the Responsiveness technology. TSW received grants from GE
Healthcare for the design and conduct of this trial, through Edinburgh
University. MK, KU, PL, MOKS, and PP are employees of GE Healthcare.
GE employees are allowed to participate in the GE shares programme.
Non-financial: none of the authors have any non-financial competing
interests relevant to the study.
Authors’ contributions
Study concept and design: TSW, KE, MOKS, KU and PP. Acquisition of data:
TSW and KE. Analysis and interpretation: MK, TSW, KE, PL, MOKS, KU and PP.
Preparation of manuscript: the manuscript was drafted by TSW and MK. All
authors contributed to the review and revision of the final manuscript. All
authors approved the final version of the manuscript and are accountable
for the accuracy and integrity of the data.
Acknowledgements
MK, PL, KU, PP, and MOKS are employees of GE Healthcare. The study was
funded through a grant from GE Healthcare to Edinburgh University and
NHS Lothian (where the study was undertaken). KE received salary support
from GE Healthcare as part of the grant to Edinburgh University and NHS
Lothian. We thank the nursing staff of the Intensive Care Unit, Edinburgh
Royal Infirmary Scotland for their enthusiastic support of the trial and for
participating in the nursing interviews.
Author details
1Anaesthetics, Critical Care and Pain Medicine, Centre for Inflammation
Research and School of Clinical Sciences, Edinburgh University, 51 Little
France Crescent, Edinburgh, Scotland EH16 4SA, UK. 2GE Healthcare Finland
Oy, Kuortaneenkatu 2, 00510 Helsinki, Finland.
Received: 8 June 2015 Accepted: 20 August 2015
References
1. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, et al. Early
intensive care sedation predicts long-term mortality in ventilated critically ill
patients. Am J Respir Crit Care Med. 2012;186:724–31.
2. Watson PL, Shintani AK, Tyson R, Pandharipande PP, Pun BT, Ely EW.
Presence of electroencephalogram burst suppression in sedated, critically ill
patients is associated with increased mortality. Crit Care Med. 2008;36:3171–7.
3. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill
patients receiving mechanical ventilation: a randomised trial. Lancet.
2010;375:475–80.
4. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative
infusions in critically ill patients undergoing mechanical ventilation. N Engl J
Med. 2000;342:1471–7.
5. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, et al.
Efficacy and safety of a paired sedation and ventilator weaning protocol for
mechanically ventilated patients in intensive care (Awakening and
Breathing Controlled trial): a randomised controlled trial. Lancet.
2008;371:126–34.
6. Brook AD, Ahrens TS, Schaiff R, Prentice D, Sherman G, Shannon W, et al.
Effect of a nursing-implemented sedation protocol on the duration of
mechanical ventilation. Crit Care Med. 1999;27:2609–15.
7. Hager DN, Dinglas VD, Subhas S, Rowden AM, Neufeld KJ, Bienvenu OJ,
et al. Reducing deep sedation and delirium in acute lung injury patients: a
quality improvement project. Crit Care Med. 2013;41:1435–42.
8. Quenot JP, Ladoire S, Devoucoux F, Doise JM, Cailliod R, Cunin N, et al.
Effect of a nurse-implemented sedation protocol on the incidence of
ventilator-associated pneumonia. Crit Care Med. 2007;35:2031–6.
9. Klompas M, Anderson D, Trick W, Babcock H, Kerlin MP, Li L, et al. The
Preventability of Ventilator-associated Events. The CDC Prevention
Epicenters Wake Up and Breathe Collaborative. Am J Respir Crit Care Med.
2015;191:292–301.
10. Miller MA, Krein SL, George CT, Watson SR, Hyzy RC, Iwashyna TJ. Diverse
attitudes to and understandings of spontaneous awakening trials: resultsfrom a statewide quality improvement collaborative*. Crit Care Med.
2013;41:1976–82.
11. Gill KV, Voils SA, Chenault GA, Brophy GM. Perceived versus actual sedation
practices in adult intensive care unit patients receiving mechanical
ventilation. Ann Pharmacother. 2012;46:1331–9.
12. Rose L, Fitzgerald E, Cook D, Kim S, Steinberg M, Devlin JW, et al. Clinician
perspectives on protocols designed to minimize sedation. J Crit Care. 2014.
doi:10.1016/j.jcrc.2014.10.021.
13. Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, et al. Clinical practice
guidelines for the management of pain, agitation, and delirium in adult
patients in the intensive care unit. Crit Care Med. 2013;41:263–306.
14. Barr J, Pandharipande PP. The pain, agitation, and delirium care bundle:
synergistic benefits of implementing the 2013 Pain, Agitation, and Delirium
Guidelines in an integrated and interdisciplinary fashion. Crit Care Med.
2013;41:S99–115.
15. Robinson BR, Berube M, Barr J, Riker R, Gelinas C. Psychometric analysis of
subjective sedation scales in critically ill adults. Crit Care Med. 2013;41:S16–29.
16. LeBlanc JM, Dasta JF, Kane-Gill SL. Role of the bispectral index in sedation
monitoring in the ICU. Ann Pharmacother. 2006;40:490–500.
17. Walsh TS, Ramsay P, Lapinlampi TP, Sarkela MO, Viertio-Oja HE, Merilainen
PT. An assessment of the validity of spectral entropy as a measure of
sedation state in mechanically ventilated critically ill patients. Intensive Care
Med. 2008;34:308–15.
18. Haenggi M, Ypparila-Wolters H, Bieri C, Steiner C, Takala J, Korhonen I, et al.
Entropy and bispectral index for assessment of sedation, analgesia and the
effects of unpleasant stimuli in critically ill patients: an observational study.
Critical Care (London, England). 2008;12:R119.
19. Weatherburn C, Endacott R, Tynan P, Bailey M. The impact of bispectral
index monitoring on sedation administration in mechanically ventilated
patients. Anaesth Intensive Care. 2007;35:204–8.
20. Walsh TS, Everingham K, Frame F, Lapinlampi TP, Sarkela MO, Uutela K, et al.
An evaluation of the validity and potential utility of facial electromyelogram
Responsiveness Index for sedation monitoring in critically ill patients. J Crit
Care. 2014;29:886. e881–887.
21. Walsh TS, Lapinlampi TP, Ramsay P, Sarkela MO, Uutela K, Viertio-Oja HE.
Responsiveness of the frontal EMG for monitoring the sedation state of
critically ill patients. Br J Anaesth. 2011;107:710–8.
22. Lapinlampi TP, Viertio-Oja HE, Helin M, Uutela KH, Sarkela MO, Vakkuri A,
et al. Algorithm for Quantifying Frontal EMG Responsiveness for Sedation
Monitoring. Can J Neurol Sci. 2014;41:611–9.
23. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The
Richmond Agitation-Sedation Scale: validity and reliability in adult intensive
care unit patients. Am J Respir Crit Care Med. 2002;166:1338–44.
24. Vivien B, Di Maria S, Ouattara A, Langeron O, Coriat P, Riou B.
Overestimation of Bispectral Index in sedated intensive care unit patients
revealed by administration of muscle relaxant. Anesthesiology. 2003;99:9–17.
25. Walsh TS, Ramsay P, Kinnunen R. Monitoring sedation in the intensive care
unit: can “black boxes” help us? Intensive Care Med. 2004;30:1511–3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
